Zynex (ZYXI) to Announce Earnings on Monday

Zynex (NASDAQ:ZYXI) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, April 28th. Analysts expect Zynex to post earnings of ($0.24) per share and revenue of $30.83 million for the quarter. Zynex has set its Q1 2025 guidance at -0.300- EPS.

Zynex (NASDAQ:ZYXI) last issued its earnings results on Tuesday, March 11th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.09 by ($0.11). Zynex had a net margin of 2.49% and a return on equity of 13.05%. The business had revenue of $45.98 million for the quarter, compared to the consensus estimate of $53.65 million. During the same quarter in the previous year, the firm posted $0.04 EPS. On average, analysts expect Zynex to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zynex Stock Down 4.4 %

NASDAQ:ZYXI opened at $2.41 on Friday. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. Zynex has a 12-month low of $1.93 and a 12-month high of $12.19. The stock’s fifty day simple moving average is $3.88 and its 200-day simple moving average is $6.66. The firm has a market capitalization of $72.85 million, a P/E ratio of 16.07 and a beta of 1.09.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ZYXI. Royal Bank of Canada reaffirmed a “sector perform” rating on shares of Zynex in a research note on Tuesday, April 15th. LADENBURG THALM/SH SH lowered shares of Zynex from a “buy” rating to a “neutral” rating in a report on Wednesday, March 12th. Finally, HC Wainwright decreased their price target on shares of Zynex from $17.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, March 12th.

Insider Activity

In related news, CFO Daniel J. Moorhead sold 10,000 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $7.15, for a total value of $71,500.00. Following the completion of the transaction, the chief financial officer now directly owns 10,050 shares of the company’s stock, valued at approximately $71,857.50. This represents a 49.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 49.28% of the stock is currently owned by company insiders.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.